drugset / Trial / NCT03767582
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Phase 1/2
Completed
22 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .
Timeline
- Start
- 2019-12-12
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CCR2/CCR5 dual antagonist | Unknown | 150 mg | Oral |
| Subject | GVAX | Vaccine | 5e+08 cells | Other |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |